

Clinical aspects and management of poisonings with cyanide

Bruno Mégarbane, MD, PhD

Medical and Toxicological Critical Care Department

Lariboisière Hospital, Paris-Diderot University

Paris - France

bruno.megarbane@lrb.aphp.fr

Introduction

- Cyanide : a potent intracellular poison, with attachment to the ferric form of necessary enzymes (cytochrome oxidase, succinic dehydrogenase, superoxide dismutase, ...)
 - It results in tissue hypoxia, acidosis, and death.
-
- ➡ Recognition of a non-classical situation of CN poisoning may be difficult.
 - ➡ Laboratory diagnosis may take hours to days
 - ➡ Early aggressive treatment with appropriate antidotes is essential

The spectrum of cyanide poisoning

- **HCN** (50 ppm, 30 min; 200-400 ppm, 1-2 min)
- **CN salts** : CN Na
CN K
CN Hg, ...
CN Au
CN Br, CN Cl
- **Nitriles** : Acetonitrile: $\text{CH}_3\text{CN} \longrightarrow \text{HCN} + \text{CH}_2\text{O}$
Propionitrile, ...
- **Nitroprusside**
- **Cyanogenic plants**
- **Stored CN salts** : $\text{CN} \longrightarrow \text{CNO}$


Conditions resulting in exposure to cyanide or cyanogen compounds

- **Household exposure:** residential fires (pipe, furniture, organic, plastics)
- **Industrial incidents:** fumigation, photographic chemicals, metallurgy, electroplating, organic synthesis, fertilizers
- **Individual or mass suicide**
- **Therapeutic exposure** to drugs such as nitroprussiate and laetrile
- **Dietary exposure** to plants such as cassava
- **Terrorist attack** (non persistent lethal agent):
 - Contamination of water
 - Food containing cyanogen compounds
 - Dispersion of cyanide gas in a closed space
 - Vector facilitating skin penetration

Smoke inhalation (1)


Each year in France :

- ❖ 250,000 fires (58% residence fires)
- ❖ 4,000 victims (< 30% burnt)
- ❖ 400 deaths




In the US: Mortality rate : 0.98 deaths / 100 000 inhabitants

Nature of fires in France over a 20 year- period



Human injuries following fire exposition in France over a 20 year-period



Smoke inhalation (2)

Fire may expose to 3 dangers:

- Thermal risk (flames, heated gases)
- Traumatic risk (blast, defenestration)
- Chemical risk



Smoke inhalation associates:

- Neurological and cardiac anoxic systemic injuries
- Ocular and respiratory irritant injuries

~ 80% of deaths are related to toxic smoke inhalation:

- | | |
|---|-----|
| - Early death (<i>per</i> exposition) | 80% |
| - Late death (<i>post</i> -exposition) | 20% |

Smoke composition

Polyintoxication: combustion or pyrolysis products in fire smokes

Compounds responsible of direct cellular anoxic toxicity :

- Carbon dioxide (CO_2)
- Carbon monoxide (CO)
- Hydrogen cyanide (HCN)
- Anhydro-derivates : sulfur dioxide, hydrogen sulfide
- Nitric oxide (NO)



Compounds responsible of mucous membrane irritant toxicity :

- Soot (particulates of polycyclic nitric and carbon compounds)
- Aldehydes : acrolein, formaldehyde, butyraldehyde, acetaldehyde, ...
- Nitrous derivates : nitric oxide and ammonia, isocyanides and amines
- Mineral acids : hydrochloric, hydrofluoric, hydrobromic acids, ...
- Carbon halogenated oxides : phosgene, chlorine
- Water vapors

Composition varies with environment

CN: residential fires, including pipe and furniture, organic materials, plastics (polyurethane), and melanine resins



Smoke inhalation \neq CO poisoning



Post-mortem HbCO in
57 fire victims

Exposition duration: 30 min




Post-mortem HbCO
in 54 cases of fatal
CO poisoning

Exposition duration: 8 à 12 h




Teige et al. Z Rechtsmedizin 1977

Relationship between N content and CN production



Ballentyne B. Clinical and experimental toxicology of cyanides, 1987

Relationship in vivo between CN and HbCO




Bertol E. *Forens Sci Int* 1983



Pathways of cyanide toxicity

A potent intracellular poison, with attachment to the ferric form of necessary enzymes (cytochrome oxidase, succinic dehydrogenase, SOD)


CN poisoning results in tissue hypoxia, acidosis and death.




CN levels in fire-related deaths



Pathways of cyanide toxicity and detoxification




Increase of CN distribution into the brain with acidosis




Djerad A. *Tox Sci* 2001

Clinical presentation

Delay in onset of clinical manifestations



Clinical presentation



Positive diagnosis

Smoke inhalation

The two fundamental signs are :

- 1)- Soot in the airways (nostrils, mouth, throats)
- 2)- Neurological impairment (Headaches, dizziness, confusion, seizures, changes in mental status, coma)



	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
<i>Carbon monoxide intoxication</i>	83	63	43	92
<i>Cyanide intoxication</i>	98	56	28	99

Vital signs in pure CO poisoning

<i>Symptoms</i>	<i>CO (mmol/l)</i>	<i>SBP (mmHg)</i>	<i>HR (/min)</i>	<i>RR (/min)</i>	<i>Lactates (mmol/l)</i>
Severe (n= 54)	2.87 ± 2.15	124 ± 19	88 ± 15	19 ± 4	3.2 ± 1.7
Moderate (n= 12)	0.84 ± 0.82	126 ± 18	85 ± 20	19 ± 3	2.3 ± 1.2
Mild (n= 65)	0.43 ± 0.56	125 ± 18	82 ± 13	19 ± 5	1.9 ± 0.9
Asymptomatic (n=15)	0.38 ± 0.45	128 ± 19	80 ± 6	17 ± 4	1.9 ± 0.7
<i>p value</i>		0.9	0.07	0.6	< 0.0001

Diagnosis of cyanide poisoning

1- Cardiovascular impairment

Hypotension, collapse, shock, or cardiac arrest
Transient reversible cardiomyopathy

2- Abnormal respiratory pattern


Polypnea, wide ventilation, hypopnea or apnea

3- Metabolic impairment

Lactate concentration > 10 mmol/l in the presence of smoke inhalation without severe burns is strongly suggestive of CN (≥ 40 $\mu\text{mol/l}$) intoxication.



Se: 87 % - Spe: 94 % - PPV: 95 %



Baud FJ. *NEJM* 1991

Occurrence of signs and symptoms in cases of CO and CN poisonings

Signs and symptoms	CO (%)	CN (%)
Headache	64	6
Dizziness	56	6
Gastro-intestinal	43	33
Altered mental status	15	13
Loss of consciousness	31	NR
Coma	25	70
Dilated pupils	6	77
Seizures	3	34
Abnormal respiratory pattern	23	95
Pulmonary oedema	6	6
Hypotension/shock	7	61
Plasma lactate (mM) + coma	2.8	13.4

Clinical symptoms among 36 cyanide intoxications* admitted to the Toxicological Intensive Care Unit at Fernand Widal Hospital in Paris, France

Symptom	N =	%
Asymptomatic	8	22
Cardiovascular collapse	10	28
Coma	13	36
Convulsions	6	17
Respiratory arrest	8	22
Metabolic acidosis	18	50
Post-anoxic coma and death	5	14
Psychomotor retardation	6	17

* Intoxications by ingestion or inhalation, excluding smoke inhalation victims

Type of Poison, Blood Cyanide and Plasma Lactate Concentrations, Clinical Status at the Time of Presentation, and Final Outcome in 11 Cases of Acute Cyanide Poisoning

	Type of Cyanide	Blood Cyanide ($\mu\text{mol/L}$)	Plasma Lactate (mmol/L)	Systolic Blood Pressure (mm Hg)	Respiratory Rate (b/min)	Glasgow Coma Score	Outcome
1	KCN	256	53.0	40	0	3	Fatal
2	KCN	239	47.7	40	0	3	Fatal
3	$\text{Hg}(\text{CN})_2$	217	19.6	60	ND	15	Survival
4	CN salt	196	21.0	0	0	3	Fatal
5	KCN	158	8.6	160	25	15	Survival
6	KCN	154	13.6	110	8	12	Survival
7	KCN	150	17.7	95	0	3	Fatal
8	KCN	125	24.6	70	ND	15	Survival
9	$\text{Au}(\text{CN})_2$ - KCN	44	4.8	120	ND	15	Survival
10	BrCN^*	13	5.1	130	18	15	Survival
11	KCN	ND*	ND*	80	0	3	Survival

Baud F. Crit Care Med 2002

Arterial Gases in 11 Cases of Acute Cyanide Poisonings


Patients	Arterial pH	Arterial PaCO ₂	Arterial PaO ₂	Anion Gap
		(mm Hg)	(mm Hg)	
1	7.16	24.2	446.6	39.0
2	7.22	53.6	84.0	37.5
3	7.33	37.2	131.3	32.4
4	7.24	19.4	513.8	49.8
5	7.36	37.4	102.8	26.4
6	7.27	18.7	169.7	19.3
7	7.38	27.0	491.3	29.3
8	ND	ND	ND	ND
9	7.38	48.0	65.3	21.7
10	7.57	22.8	94.2	21.4
11	ND	ND	ND	ND

ND : denotes not determined.


Baud F. Crit Care Med 2002

**Correlation
between the
plasma lactate
concentrations
and the systolic
blood pressure,
the arterial pH,
and the anion gap
before antidotal
treatment**


Baud F. Crit Care Med 2002



$r = 0.87$
 $p = 0.002$



$r = 0.87$
 $p = 0.0004$




$r = 0.83$
 $p = 0.008$

Correlation of blood cyanide and plasma lactate before antidotal treatment

Before antidotal treatment :


- The median plasma lactate concentration was 18.6 mmol/L
- The median blood cyanide concentration was 155.9 $\mu\text{mol/L}$.



$r = 0.74$
 $p = 0.017$

Relationship of
plasma lactate
concentrations
to blood CN
levels in a
patient
with pure acute
CN poisoning

Baud F. *BMJ* 1996



CN: 256 μmol/l - T1/2: 1.14 h


Lactate: 53 mmol/l - T1/2: 3.94 h

Time course of blood cyanide concentration, plasma lactate concentration, and arteriovenous oxygen saturation in a case of pure cyanide poisoning

Origin of lactate in poisonings ?

- Lactic acidosis is not specific. Various toxicants can induce lactic acidosis : CO, Azide, H₂S, ...
- Several factors can contribute to lactic acidosis :
 - Cardiovascular failure
 - Apnea
 - Seizures
 - Acute liver failure
 - Catecholamine rush
 - Mitochondrial dysfunction


Interest of lactate measurement in cyanide poisoning



Sensitivity : 94 %
Specificity : 70 %
PPV: 64 %
NPV: 98 %

Baud F. *Crit Care Med* 2002

TK-TD relationships in 2 cases of CN poisoning



Patients	E ₀ (mmol/L)	E _{max} (mmol/L)	C ₅₀ (μmol/L)	N	R ²
1	0.3 (4.2)	55.7 (7.9)	62.6 (8.6)	2.2 (0.6)	0.981
6	1.4 (0.2)	12.1 (0.4)	45.5 (1.1)	5.4 (0.9)	0.998

$$E = E_{\max} * C^n / [C_{50}^n + C^n] + E_0$$

Does Cyanide toxidrome exist ?

Most frequent presentation = Rapid onset of (N = 86)

Neurological symptoms	73 %
Mydriasis	71 %
Seizures	30 %
Cardiovascular symptoms	
Tachycardia	99 ± 33 / min
Reduction in SBP	103 ± 30 mmHg
Abnormal respiratory pattern	92 %
without pulmonary edema	94 %
Metabolic acidosis	7.20 ± 0.24
lactate increase	16.9 ± 11 mmol/l
SvO ₂ arteriolization	$89.5 \pm 6.2\%$
Cardiac arrest (10 %), death (24 %)	

Conventional treatment of CN poisoning

Conventional treatment of cyanide poisoning includes

- Decontamination
- Supportive treatment
- Specific treatment: antidotes



Decontamination

- Decontamination attempts to decrease the bioavailability of cyanide.
- Decontamination should be adapted to the conditions of cyanide poisoning.
- Does decontamination improves the prognostic of this poisoning ?



Decontamination should be performed but never postpone supportive treatment.


Supportive treatment

- Basic life-support of CN poisoning includes :
 - 1- Immediate administration of high flow of oxygen,
 - 2- Protection of the airways,
 - 3- Cardiopulmonary resuscitation.


- Advanced life support includes:
 - 1- Endotracheal intubation in comatose patients
 - 2- Anti-epileptic drugs in case of seizures,
 - 3- Epinephrine infusion to correct cardiovascular collapse,
 - 4- Sodium bicarbonate to correct deep metabolic acidosis.

- Supportive treatment is efficient in pure CN poisoning.

THERAPEUTIC OPTIONS IN CYANIDE POISONING



THERAPEUTIC OPTIONS IN CYANIDE POISONING



Oxygen + hydroxocobalamin \pm sodium thiosulfate
A combination treatment for all symptoms

Therapeutic strategies of this rare poisoning

➡ should take into account for the most common cause of cyanide poisoning in western countries, i.e. smoke inhalation which always results in a poly-intoxication involving CO.

An emergency antidote is an available drug
allowing a right to error = safety first + proven
efficiency

The list of antidotes to cyanide

Toxicodynamic treatment

⌘ Oxygen

⌘ Methaemoglobin forming agents

⌘ Nitrites

⌘ DMAP (dimethylaminophenol)

⌘ Cobalt compounds

⌘ Dicobalt EDTA

⌘ Hydroxocobalamin

⌘ Sulfur donors

⌘ Thiosulfate

Toxicokinetic
treatments

The only available FDA-approved antidote in the US until 6 years ago was the **Pharmaceutical Cyanide Antidote Kit**

Contains 3 components:

- **Amyl nitrite pearls:**

In the absence of IV access, gauze sponge soaked in amyl nitrite 30 sec each min or held between the O₂ source and the mouth

- **A solution of 3% sodium nitrite:**

10 ml (0.33 ml/kg) IV 2-4 times 100-150 ml solution

Repeat at half the initial dose in absence of response

Produce 30% Me

+ Vasopressor (e.g., vasodilatation)

- **25% sodium thiosulfate:**

50 ml (1.65 ml/kg)





Dicobalt EDTA (Kelocyanor®)

- Currently used in Europe but not available in the USA
- Dose: 300-600 mg IV over 15-30 minutes
- Repeat dose in 2-4 hours if no improvement
- **Adverse effects:** tachypnea, cardiovascular and hemodynamic instability, seizures, gastrointestinal symptoms, angioedema, allergic manifestations

I do not use it



Thiosulfate

- Rhodanese, a sulfur transferase located in mitochondria: irreversible transfer of a sulfane from cyanide to thiosulfate to CN
- Large doses required, since poor intracellular penetration. Limited interest in oral use since slow detoxification ($t_{1/2}$: 26 h)
- Dose: 8 - 16 g in infusion, after initial bolus.
- Use in cyanide poisoning (CN hepatic production).







Hydroxocobalamin (Cyanokit)

- Currently used in Europe and recently approved in the USA
- 50 g of hydroxycobalamin + 2.5 g of sodium cyanide
- Dose: 5 g (70 mg/kg) IV (15 min), repeated according to seriousness (5-10 g).
- Ability to cross the blood-brain barrier
- Adverse effects: reddish discoloration of the skin and urine, allergic


I systematically use it

Hydroxocobalamin molecule




Intraosseous vs. intravenous infusion of hydroxocobalamin to treat acute severe cyanide toxicity in a swine model


Heart rate




MAP




Brain O₂ saturation Cardiac output



Lactates




Cyanide




Bebarta VS. Acad Emerg Med 2014

Assessment of hydroxocobalamin efficiency in experimental studies of cyanide poisoning


Fifty-four beagle dogs were poisoned by IV administration of a potentially lethal dose of potassium cyanide.



Borron SW. *Clin Tox* 2006




Prospective study of fire victims treated with empiric hydroxocobalamin



67% survivors among the 42 patients confirmed *a posteriori* to have had CN poisoning.

Well-tolerated treatment irrespective of the presence of CN poisoning.

Borrón SW. Ann Emerg Med 2007






Utility and outcomes of hydroxocobalamin use in smoke inhalation patients

	Overall (n = 273)	Hydroxocobalamin (n = 138)	No hydroxocobalamin (n = 135)	p
7 day creatinine difference (mg/dL), median (IQR)	0.09 (-0.05 to 0.29)	0.09 (-0.04 to 0.24)	0.08 (-0.50 to 2.81)	0.95
Pneumonia, n (%)	97 (35.5)	31 (22.5)	66 (48.9)	<0.01
Ventilator days ^a , median (IQR)	5.0 (2-13)	4.0 (1-10)	7.0 (3-16)	<0.01
Vent-free days (VFD) ^b , median (IQR)	15.0 (0-25)	20.0 (0-26)	11.0 (0-24)	0.02
ICU LOS, days, median (IQR)	6.0 (2-15)	5.0 (2-13)	10 (4-20)	0.03
HLOS, days, median (IQR)	10.0 (3-20)	7.0 (3-18)	11.0 (5-24)	0.06
Mortality, n (%)	78 (28.6)	40 (29.0)	38 (28.1)	0.89

Routine administration was associated with lower rate of pneumonia, faster liberation from the ventilator, and reductions in ICU stay

Nguyen L. Burns 2017

Prehospital administration of hydroxocobalamin for smoke inhalation-associated CN Poisoning: 8 years of experience in the Paris Fire Brigade



Fortin JL. Clin Toxicol 2007

Cardiac disorders in smoke inhalation-associated CN poisoning

Cardiac Disorder	Number
Cardiocirculatory arrest	
Asystole	58
Ventricular fibrillation	3
Repolarization disorders	
Myocardial ischemia	5
Subendocardial lesion	7
Conduction disorders	
Intracardiac	5
Rhythm disorders	
Supraventricular tachycardia	56
Ventricular tachycardia	1
Total	135

61 patients with cardiorespiratory arrest


30 patients died at the scene despite antidotal treatment
24 adults + 6 children
Mean adult hydroxocobalamin dose used = 4.37 ± 1.10 grams
Mean pediatric hydroxocobalamin dose used = 2.30 ± 0.44 grams

26 patients who recovered spontaneous cardiac activity after antidotal treatment with subsequent death in hospital
24 adults + 2 children
Mean adult hydroxocobalamin dose used = 6.04 ± 2.07 grams


5 adult patients surviving without any sequelae, particularly neurological
Mean adult hydroxocobalamin dose used = 7.50 ± 2.5 grams
Mean cyanide levels before antidotal administration = 4.76 ± 1.92 mg/L [3.4–6.12 mg/L]

**EuSEM guidelines
2012**


Pre-hospital algorithm



Hospital algorithm





Hydroxocobalamin pharmacokinetics



Typical PK profile from a severely CN poisoned patient treated with a 5-g hydroxocobalamin (OHCbl). The initial cyanide level was $128 \mu\text{M}$. Formation of cyanocobalamin (CNCbl) was immediately observed, indicating the rapid complexation of cyanide by OHCbl, followed by the elimination of the excess OHCbl and the formed CNCbl

Astier A. Chromatogr 1995

Relation of blood CN to plasma cyanocobalamin concentration after a fixed dose of hydroxocobalamin



- **Hydroxocobalamin** 5 g can bind all available CN for CN up to 40 μM .
- A cut-off of 300 $\mu\text{mol/L}$ is the maximum amount of cyanocobalamin able to be formed after hydroxocobalamin 5 g dose.
- **Urinary cyanocobalamin** correlateq linearly with the initial blood CN for those patients with blood CN < 40 μM .

Houeto P. Lancet 1995



Interactions with other drugs

- HOC_o mixed with S₂O₃Na₂
→ inefficient thiosulphato-cobalamin
Evans CL. Br J Pharmacol 1964

- HOC_o is a chelating agent of NO
Rajanayagam et al. Br J Pharmacol.1993

Potential interference by hydroxocobalamin

Cooximetry hemoglobin measurement



Lee J. Ann Emerg Med 2007


Spectrophotometric assays on the Beckman Coulter DxC and AU680 analyzers : ALT, amylase, total bilirubin, cholesterol, creatine kinase, creatinine, magnesium, uric acid.

+ On the DxC; direct bilirubin, iron, phosphate, protein and triglycerides

Ranjitkar P, Acta Clin Chem 2015


Blood leak alarm interference by hydroxocobalamin is hemodialysis machine dependent

Dialysis machine	Manufacturer	Is Pseudo-blood leak likely to happen with hydroxocobalamin use?
Althin	Baxter	No
C3	Cobe/Gambro	No
DBB 06	Nikkiso	Yes
DCS-6	Nipro	Unknown
Dialog Plus	B-Braun	Yes
Diapact	B-Braun	Yes
Diamax	Nipro	Unknown
Formula 2000 Plus	Bellco	No
Formula 2000 Domus Plus	Bellco	No
Fresenius 2008K	Fresenius	Yes
MDS 101	Asahi	No
MR100B	C-THME	Unknown
NCU-8	Nipro	Unknown
NxStage	NxStage	No
Phoenix	Gambro	No
Prismaflex	Gambro	No



*Sutter ME. Clin Tox 2012
Avila J. Clin Nephrol 2012*

Risk of oxalate nephropathy with the use of hydroxocobalamin in critically ill burn patients



The patients treated with hydroxocobalamin ($n = 19$) had an increased risk of AKI (OR: 5.8 [1.6-20.7]) and RRT (OR: 4.3 [1.09-17]). Association between AKI and hydroxocobalamin remained after adjusting for abbreviated burn severity index, SAPSII, and lactate on admission.

Legrand M. Intensive Care Med 2016
Megarbane B. Intensive Care Med 2016


Safety of antidotes to cyanide

Regarding the main clinical condition of cyanide poisoning, i.e. smoke inhalation, we should take into account not only for the efficiency but also for the safety of the antidotal treatment

- **Methemoglobin forming agents** impair the transport and delivery of oxygen to tissues.
- **Cobalt EDTA** : numerous side-effects.
- **Sodium thiosulfate** is safe.
- **Hydroxocobalamin** is safe. However, the risk of oxalate nephropathy cannot be excluded in the subset of critically burnt smoke-poisoned patients.

Nitroprusside and nitriles poisonings

- ◆ Adequate thiosulfate store = limiting step
- ◆ Treatment of life-threatening events : **hydroxocobalamin**
- ◆ Prevention of recurrent toxicity: **sodium thiosulfate**
- ◆ If persistent lactic acidosis: **disulfiram** to inhibit CN production



De Paepe P. Clin Tox 2016


Complications and sequelae

- Post-anoxic encephalopathy
- CO-related post-interval syndrome
- CN-related brain injuries

F 50 years, comatose, pulseless and apneic, CPR + 2.5 g HCob +HBO
Blood cyanide ($68 \mu\text{M}$) HBCO (10.9%)

- Extraparapyramidal hypertonia, choreo-athetotic movements
- MRI: increased cerebral atrophy, in the white matter, hemorrhagic putamini and globi pallidi; but respect of hippocampi

Baud FJ. *BMJ Case Reports* 2011



Experimental tested antidotes:

Nucleophiles (alphaketoglutarate, dihydroxyacetone):

- ◆ Bind to CN, reducing its availability to cytochrome oxidase
- ◆ Decreased toxicity in animal models
- ◆ Increased efficiency by the addition of thiosulfate

Other modalities under investigation:

- ◆ Isosorbide dinitrate
- ◆ Dinitrocobinamide (Vit B12 analogue, IM)
- ◆ Sulfanegen (3-mercaptopyruvate sulfurtransferase)
- ◆ NMDA inhibitors
- ◆ Nitrous oxide
- ◆ Antioxydants

Take home message (1)

Both experimental and clinical data support the assumption that antidotal treatment is beneficial in cyanide poisoning.

- ➡ **Sodium thiosulfate:**
efficient - safe
delayed action
- ➡ **MetHb forming agents:**
potent
risk of impairment of oxygen delivery to the tissue
- ➡ **Cobalt EDTA:**
very potent - immediate action - effective if late
numerous side effects
- ➡ **Hydroxycobalamin:**
less potent - immediate action - safe

Take home message (2)

In patients suspected of CN poisoning:

- We recommend the use of hydroxocobalamin as first-line antidote according to its safety
- in association with supportive treatment
- administered as rapidly as possible.

In massive CN poisoning (ingestion) or nitriles poisoning, the potency of hydroxocobalamin even at high dose is limited

➡ The continuous infusion of sodium thiosulfate +/- disulfiram should be recommended